Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV) Nov 4, 2025
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital Oct 15, 2025
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy Oct 7, 2025
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office Sep 17, 2025
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest Aug 21, 2024
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America Aug 14, 2024
